scholarly journals Long-Term Effects of Iron Chelating Agents on Ocular Function in Patients with Thalassemia Major

2021 ◽  
Vol Volume 15 ◽  
pp. 2099-2109
Author(s):  
Raffaele Nuzzi ◽  
Giada Geronazzo ◽  
Federico Tridico ◽  
Alessia Nuzzi ◽  
Paolo Caselgrandi ◽  
...  
Keyword(s):  
Chelating Agents ◽  
Thalassemia Major ◽  
Long Term Effects ◽  
Iron Chelating Agents

scholarly journals Olfactory Dysfunction in β Thalassemia Major Patients Treated With Iron-Chelating Agents

2019 ◽  
Vol 98 (8) ◽  
pp. NP125-NP130
Author(s):  
Serhan Derin ◽  
Selvet Erdogan ◽  
Murat Sahan ◽  
Mehmet Fatih Azik ◽  
Hatice Derin ◽  
...  
Keyword(s):  
Chelating Agents ◽  
Thalassemia Major ◽  
Olfactory Dysfunction ◽  
Facial Trauma ◽  
Control Group ◽  
Control Groups ◽  
History Of ◽  
And Control ◽  
Iron Chelating Agents

Ocular and ophthalmological adverse effects may be seen in β-thalassemia major (BTM) patients treated with regular blood transfusions and iron-chelating agents. We hypothesized that olfactory dysfunction may be present in this population. In this study, we aimed to investigate olfactory dysfunction in patients with BTM and determine the etiological factors. A total of 43 patients with BTM were included in the study. Forty-three patients without any nasal complaints, history of facial trauma, or nasal surgery were included as the controls. All participants had nasal endoscopy. The iron-chelating agents used, their duration of use, as well as hemoglobin and ferritin levels of the BTM patients were recorded. Sniffin’ Sticks test (SST) was used to assess olfactory functions, and BTM and control groups were compared for the results. The correlations of SST scores with the other study parameters were analyzed. Eight (18.6%) of 43 patients in the BTM group had hyposmia while none of the patients in the control group had hyposmia ( P < .001). Older age, low-hemoglobin level, and longer use of deferoxamine were found to be correlated with olfactory dysfunction. Olfactory dysfunction may be seen in BTM patients treated with iron-chelating agents. The results of this study suggest that screening for olfactory function may be needed in routine follow-up of BTM patients.

scholarly journals Olfactory Dysfunction in β-Thalassemia Major Patients Treated with Iron-Chelating Agents

2017 ◽  
Vol 96 (10-11) ◽  
pp. E8-E12 ◽  
Author(s):  
Serhan Derin ◽  
Selvet Erdogan ◽  
Murat Sahan ◽  
Mehmet Fatih Azik ◽  
Hatice Derin ◽  
...  
Keyword(s):  
Chelating Agents ◽  
Thalassemia Major ◽  
Olfactory Dysfunction ◽  
Olfactory Function ◽  
Facial Trauma ◽  
Control Group ◽  
History Of ◽  
And Control ◽  
Iron Chelating Agents

Ocular and ophthalmologic adverse effects may occur in patients with β-thalassemia major (BTM) treated regularly with blood transfusions and iron-chelating agents. We hypothesized that olfactory dysfunction may be present in this patient population. We aimed to investigate olfactory dysfunction in patients with BTM and to determine etiologic factors. A total of 43 patients with BTM were included in the study. Forty-three subjects without nasal complaints, history of facial trauma, or nasal surgery were included as the controls. All participants had nasal endoscopy. The use of iron-chelating agents by patients with BTM and their duration of use were recorded, as well as hemoglobin and ferritin levels. The Sniffin Sticks test (SST) was used to assess olfactory function, comparing results between the BTM and control groups. The correlations of SST scores with the other study parameters were analyzed. Eight (18.6%) of 43 patients in the BTM group and none of the subjects in the control group had hyposmia (p < 0.001). Older age, low hemoglobin level, and longer use of deferoxamine were found to be correlated with olfactory dysfunction. Olfactory dysfunction can occur in patients with BTM treated with iron-chelating agents. The results suggest that screening for olfactory function should be part of the routine follow-up of patients with BTM.

Intensive Transfusion Therapy in Thalassemia Major

PEDIATRICS ◽  
1967 ◽  
Vol 40 (5) ◽  
pp. 911-915
Author(s):  
MICHAEL E. J. BEARD ◽  
THOMAS F. NECHELES ◽  
DONALD M. ALLEN
Keyword(s):  
Chelating Agents ◽  
Clinical Course ◽  
Thalassemia Major ◽  
Iron Loading ◽  
Short Term ◽  
Transfusion Therapy ◽  
Cardiac Symptoms ◽  
Clinical Benefits ◽  
Symptoms And Signs

A hemoglobin level of over 10 gm per 100 ml has been maintained by transfusion in six children with thalassemia major. Chelating agents have been used to minimize the increase in iron loading. Striking clinical improvement with regression of abnormal cardiac symptoms and signs was seen in all these patients. It is concluded that, in thalassemia major, this therapy provides at least short-term clinical benefits to severely affected children. The rationale for long-term, intensive transfusion therapy is based on the assumption that it is the degree of anemia rather than the degree of iron loading which leads to the eventual cardiac failure and death in these patients. Proof of this hypothesis will depend to some extent on the subsequent clinical course of these children.

Ovarian Dysfunction in Fetally Irradiated Beagles

1977 ◽  
Vol 35 ◽  
pp. 658-659
Author(s):  
T. M. Seed ◽  
M. H. Sanderson ◽  
D. L. Gutzeit ◽  
T. E. Fritz ◽  
D. V. Tolle ◽  
...  
Keyword(s):  
Gamma Rays ◽  
Low Dose ◽  
Long Term Effects ◽  
Ovarian Dysfunction ◽  
Dose Rates ◽  
Highly Sensitive ◽  
Microscopic Evaluation ◽  
Ovarian Pathology ◽  
Normal Offspring

The developing mammalian fetus is thought to be highly sensitive to ionizing radiation. However, dose, dose-rate relationships are not well established, especially the long term effects of protracted, low-dose exposure. A previous report (1) has indicated that bred beagle bitches exposed to daily doses of 5 to 35 R 60Co gamma rays throughout gestation can produce viable, seemingly normal offspring. Puppies irradiated in utero are distinguishable from controls only by their smaller size, dental abnormalities, and, in adulthood, by their inability to bear young.We report here our preliminary microscopic evaluation of ovarian pathology in young pups continuously irradiated throughout gestation at daily (22 h/day) dose rates of either 0.4, 1.0, 2.5, or 5.0 R/day of gamma rays from an attenuated 60Co source. Pups from non-irradiated bitches served as controls. Experimental animals were evaluated clinically and hematologically (control + 5.0 R/day pups) at regular intervals.

Ultrastructural investigations of MDL 19,660-induced effects on the canine platelet and megakaryocyte

1990 ◽  
Vol 48 (3) ◽  
pp. 374-375
Author(s):  
D.E. Loudy ◽  
J. Sprinkle-Cavallo ◽  
J.T. Yarrington ◽  
F.Y. Thompson ◽  
J.P. Gibson
Keyword(s):  
Antidepressant Drug ◽  
Beagle Dogs ◽  
Long Term Effects ◽  
Short Term ◽  
Platelet Counts ◽  
Toxicological Studies ◽  
Induced Aggregation ◽  
Internal Architecture

Previous short term toxicological studies of one to two weeks duration have demonstrated that MDL 19,660 (5-(4-chlorophenyl)-2,4-dihydro-2,4-dimethyl-3Hl, 2,4-triazole-3-thione), an antidepressant drug, causes a dose-related thrombocytopenia in dogs. Platelet counts started to decline after two days of dosing with 30 mg/kg/day and continued to decrease to their lowest levels by 5-7 days. The loss in platelets was primarily of the small discoid subpopulation. In vitro studies have also indicated that MDL 19,660: does not spontaneously aggregate canine platelets and has moderate antiaggregating properties by inhibiting ADP-induced aggregation. The objectives of the present investigation of MDL 19,660 were to evaluate ultrastructurally long term effects on platelet internal architecture and changes in subpopulations of platelets and megakaryocytes.Nine male and nine female beagle dogs were divided equally into three groups and were administered orally 0, 15, or 30 mg/kg/day of MDL 19,660 for three months. Compared to a control platelet range of 353,000- 452,000/μl, a doserelated thrombocytopenia reached a maximum severity of an average of 135,000/μl for the 15 mg/kg/day dogs after two weeks and 81,000/μl for the 30 mg/kg/day dogs after one week.

Long-Term Effects of Head Lice Tx Unknown

2012 ◽  
Vol 43 (3) ◽  
pp. 42
Author(s):  
MITCHEL L. ZOLER
Keyword(s):  
Head Lice ◽  
Long Term Effects
Sign in / Sign up

Export Citation Format

Share Document